Foreword

Lasic D & Martin F , eds. Stealth Liposomes. Boca Raton: CRC Press, 1995.

Benjamin RS , Wiernik PH & Bachur NR Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent singe high-dosage schedule. Cancer 1974; 33: 19-27.

Minow RA , Benjamin RS , Lee ET & Gottlieb JA Adriamycin cardiomyopathy: Risk factors. Cancer 1977; 39: 1397-402.

Von Hoff DD , Layard MW , Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979; 91: 710-7.

Maral RJ & Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treatment Reports 1981; 65 (Supplement 4): 9-18.

Wright JC Cancer chemotherapy: Past, present and future - Part I. Journal of the National Medical Association 1984; 76: 773-84.

Legha SS , Hortobagyi GN & Benjamin RS ( JJ Lokich , ed.) Anthracyclines. Cancer Chemotherapy by Infusion. Chicago: Precept Press, 1987 pp. 130-44.

Pigram WJ , Fuller W. & Hamilton LD Stereochemistry of intercalation. Interaction of daunomycin with DNA . Nature 1972; 235: 17-9.

Pindur U. , Haber M. & Sattler K. Antitumor active drugs as intercalators of deoxyribonucleic acid. Journal of Chemical Education 1993; 4: 263-72.

Zhang H. , Gao Y. , van de Marel GA & Wang AH-J. Simultaneous incorporations of two anticancer drugs into DNA. Journal of Biological Chemistry 1993; 268: 10095-101.

Hickman J. , Chahwala SB & Thompson EG Interaction of the antibiotic Adriamycin with the plasma membrane . Advances in Enzyme Regulation 1985; 24: 263 -74.

Santone KS , Oakes SG , Taylor SR & Powis G. Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. Cancer Research 1986; 46: 2659-64.

Pommier Y. , Schwartz RE , Zwelling LA & Kohn KW Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 1985; 24: 6406-10.

Tewey KM , Rowe TC , Yang L. , Halligan BD & Liu LF Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.

Bachur NR , Gee MV & Gordon SL Enzymatic activation of actinomycin D ACTD to free radical state. Proceedings of the American Association of Cancer Research 1978; 19: 75-9.

Berlin V. & Haseltine WA Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. Journal of Biological Chemistry 1981 ; 256: 4747-56.

Powis GP Metabolism and reactions of quinoid anticancer agents. Pharmacological Therapeutics 1987; 35: 57-162.

Zwelling LA , Kerrigan D. & Michael S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells. Comparison with Adriamycin and 4'-9-acridinylamino methanesulfono-m-anisidine . Cancer Research 1982; 42: 2687-91.

Needham D. , McIntosh TJ & Lasic DD Repulsive interactions and mechanical stability of polymer-grafted lipid membranes . Biochimica Biophysica Acta 1992; 1108: 40-8.

Dvorak HF , Nagy JA , Dvorak JT & Dvorak AM Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. American Journal of Pathology 1988; 133: 95-109.

Wu NZ & Dewhirst MW Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy. Microvascular Research 1993 ; 46: 231 - 53.

Speth Paj , van Hoesel Qgcm & Haanen C. Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics 1988; 15: 15-31.

Greene RF , Collins JM , Jenkins JF , Speyer JL & Myers CE Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Research 1983; 43:43: 3417-21.

Speth Paj , Linssen Pcm , Holdrinet Rsg & Haanen C. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clinical Pharmacology and Therapeutics 1987; 41: 661-5.

Speth Paj , Linssen Pcm , Boezeman Jbm , et al. Cellular and plasma Adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemotherapy and Pharmacology 1987; 20: 305-10.

Yesair DW , Schwartzbach E. , Shuck D. , Denine EP & Asbell AS Comparative pharmacokinetics of Daunomycin and Adriamycin in several animal species. Cancer Research 1972; 32: 1177-83.

Ozols RF , Locker GY , Doroshow JH , Grotzinger KR , Myers CE & Young RC Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer . Cancer Research 1979; 39: 3209-14.

Oosterbaan MJ , Dirks RJ , Vree TB & van der Kleijn E. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. Pharmaceutical Research 1984; 1: 33 -8.

Cusack BJ , Young SP , Loseke VL , Hurty MR , Beals L. & Olson RD Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemotherapy and Pharmacology 1992; 30: 145-8.

Riggs CE , Benjamin RS , Serpick AA & Bachur NR Biliary disposition of Adriamycin. Clinical Pharmacology and Therapeutics 1977; 22: 234-41.

Benjamin RS , Riggs CE & Bachur NR Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 1977; 37: 1416-20.

Takanashi S. & Bachur NR Adriamycin metabolism in man, evidence for urinary metabolites. Drug Metabolism and Disposition 1976; 4: 79-87.

Gabizon A. , Barenholz Y. & Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharmaceutical Research 1993; 10: 703-8.

Gabizon A. , Catane R. , Uziely B. , et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes . Cancer Research 1994; 54: 987-92.

Legha SS , Benjamin RS , Mackay B. , et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982 ; 49: 1762-6.

Lokich JJ & Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome . Annals of Internal Medicine 1984; 101: 798-800.

Vogelzang NJ & Ratain MJ Cancer chemotherapy and skin changes . Annals of Internal Medicine 1985; 103: 303-4.

Riggs CE , Jr. & Bachur NR ( MM Ames , G Powis , & JS Kovach , eds.) Clinical pharmacokinetics of anthracycline antibiotics. Pharmacokinetics of Anticancer Agents in Humans. Amsterdam and New York: Elsevier, 1983 pp. 229-78.

Johnson AH , Darpatkin HH & Newman J. Clinical investigation of intermediate-and high-purity antihaemophilic factor (factor VIII) concentrates. British Journal of Hematology 1971; 21: 21-41.

Shaffer CB & Critchfield FH The absorption and excretion of the solid polyethylene glycols. Journal of the American Pharmacological Association 1947; 36: 152-7.

Carpenter CP , Woodside MD , Kinkead ER , King JM & Sullivan LJ Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicology and Applied Pharmacology 1971; 18: 35-40.

Jaenke RS An anthracycline antibiotic-induced cardiomyopathy in rabbits. Laboratory Investigation 1974; 30: 292 - 304.

Iatropoulos MJ Anthracycline cardiomyopathy: Predictive value of animal models. Cancer Treatment Symposium 1984; 3: 3-17.

Thompson D. , Molello JA , Strebing RJ et al. Teratogenicity of Adriamycin and Daunomycin in the rat and rabbit. Teratology 1978; 17: 151-8.

Physicians' Desk Reference 45th Edition. Oradell NJ: Medical Economics Data , 1991, pp. 559-62.

Ansell GB , Dawson Rmc & Hawthorne NJ Form and Function of Phospholipids. Amsterdam: Elsevier, 1973.

Smyth HF , Carpenter CP & Weil CS The chronic oral toxicity of the polyethylene glycols. Journal of the American Pharmacological Association 1950; 44: 27-30.

Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemotherapy Reports 1966; 50: 219-44.

Wolf A. , Saito T. , Dudek R. & Bing RJ The effect of lysophosphatidylcholine on coronary and renal circulation in the rabbit. Lipids 1991; 26: 223-6.

Rudolph R. , Stein RS & Pattillo RA Skin ulcers due to Adriamycin. Cancer 1976 ; 38: 1087-94.

Samuels BL , Vogelzang NJ , Ruane M. & Simon MA Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treatment Reports 1987; 71: 971-2.

Ackland SP , Ratain MJ , Vogelzang NJ , Choi KE , Ruane M. & Sinkule JA Pharmacokinetics and pharmacodynamics of long-term continuous-infusion of doxorubicin. Clinical Pharmacology and Therapeutics 1989; 45: 340-7.

Dantchev D. , Slioussartchouk V. , Paintrand M. , Hayat M. , Bourut C. & Mathe G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of Golden hamsters with Adriamycin, Detorubicin, AD-32 and Aclacinomycin. Cancer Treatment Reports 1979; 63: 875-88.

Lu CC & Meistrich ML Cytotoxic effects of chemotherapeutic drugs on mouse testis cells . Cancer Research 1979; 39: 3575-82.

Chapman RM , Sutcliffe SB , Rees LH , Edwards Crw & Malpas JS Cyclical combination chemotherapy and gonadal function. Lancet 1979; 1: 285-9.

Whitehead E. , Shalet SM , Blackledge G. , Todd I. , Crowhter D. & Beardwell CG The effects of Hodgkin's disease and combination chemotherapy on gonadal infusion in the adult male . Cancer 1982; 49: 418-22.

Fuse H. , Iwasaki M. & Katayama T. Endocrine/ histological parameters of spermatogenic damage in doxorubicin-treated rats. Advances in Controlled Delivery Systems 1992; 8: 33-40.

Bertazzoli C. , Chieli T. , & Solcia E. Different incidence of breast carcinomas or fibroadenomas in Daunomycin or Adriamycin treated rats. Experientia 1971; 27: 1209-10.

Solcia E. , Ballerini L. , Bellini O. , Sala L. , & Bertazzoli C. Mammary tumors induced in rats by Adriamycin and Daunomycin. Cancer Research 1978; 38: 1444-6.

Gabizon A. , Amselem S. , Goren D. , et al. Preclinical and clinical experience with a doxorubicin-liposome preparation. Journal of Liposome Research 1990; 1: 491-502.

Gabizon A. , Chisin R. , Amselem S. et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. British Journal of Cancer 1991; 64: 1125 -32.

Wu NZ , Da D. , Rudoll TL , Needham D. , Whorton AR & Dewhirst MW Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Research 1993; 53: 3765-70.

Huang SK , Lee K-D., Hong D. , Friend DS & Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Research 1992; 52: 5135-43.

Huang SK , Martin FJ , Jay G. , Vogel J. , Papahadjopoulos D. & Friend DS Extravasation and transcytosis of liposomes in Kaposi's Sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. American Journal of Pathology 1993; 143: 10-14.

Woodle MC & Lasic DD Sterically stabilized liposome. Biochimica Biophysica Acta 1992; 1113: 171-99.

Chlebowski RT , Paroly WS , Pugh RP , et al. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence cardiotoxicity . Cancer Treatment Reports 1980; 64: 47-51.

Lokich JJ , Bothe A. , Zipoli T. et al. Constant infusion schedule for Adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. Journal of Clinical Oncology 1983; 1: 24-8.

Tietz NW Clinical Chemistry. Philadelphia: WB Saunders Company, 1986.